Ketamine

MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%

Retrieved on: 
Wednesday, November 29, 2023
Absorption, Caco-2, Depression, Research, Safety, Hope, MIRA, Projection, DSM-IV codes, IQVIA, Patient, Esketamine, MBBS, MD, TRD, Drug development, Drug, Suicidal ideation, Mouth, MDSI, Pharmaceutical industry, Ketamine

BALTIMORE, Nov. 29, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical company focused on neurologic diseases and neuropsychiatric disorders, today announced results from recent studies that indicate Ketamir-2's oral bioavailability is predicted to be approximately 80%.

Key Points: 
  • BALTIMORE, Nov. 29, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical company focused on neurologic diseases and neuropsychiatric disorders, today announced results from recent studies that indicate Ketamir-2's oral bioavailability is predicted to be approximately 80%.
  • Given oral Ketamine's previously determined 23% bioavailability when taken by mouth, Ketamir-2's adjusted oral bioavailability based on the CaCO-2 results is predicted to be around 80%1.
  • "This positive financial outlook bolsters our confidence in advancing Ketamir-2's clinical development," said Erez Aminov, Chief Executive Officer of MIRA Pharmaceuticals.
  • This advancement is not just a milestone for MIRA Pharmaceuticals, but a beacon of hope for millions battling severe depression."

MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2

Retrieved on: 
Monday, November 20, 2023
Principal, Safety, Johns Hopkins, MIRA, DSM-IV codes, Hope, CSA, Chairperson, Controlled Substances Act, FDA, Depression, National Network, MD, Partnership, TRD, DEA, Doctor of Philosophy, Suicidal ideation, Mental health, Take-home naloxone program, MDSI, Schedule, Pharmaceutical industry, Ketamine, Esketamine

BALTIMORE, Nov. 20, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical company, today announced a partnership with MIRALOGX, LLC, an intellectual property holding company established by MIRA's founder. Under an exclusive licensing agreement, MIRA will have the exclusive right in the U.S., Canada, and Mexico to develop and commercialize Ketamir-2, a novel oral ketamine analog designed to revolutionize the landscape of depressive disorder treatments. This transformative collaboration includes a a $3 million line of credit extended by MIRALOGX to fund the initial development of Ketamir-2.

Key Points: 
  • Under an exclusive licensing agreement, MIRA will have the exclusive right in the U.S., Canada, and Mexico to develop and commercialize Ketamir-2, a novel oral ketamine analog designed to revolutionize the landscape of depressive disorder treatments.
  • This transformative collaboration includes a a $3 million line of credit extended by MIRALOGX to fund the initial development of Ketamir-2.
  • Unlike Ketamine, which necessitates intravenous, intramuscular, or intranasal administration due to its limited oral bioavailability, in initial pre-clinical studies, Ketamir-2 appears to exhibit a more clinically desirable gastrointestinal absorption profile.
  • The combination of this exclusive licensing agreement and obtaining initial funding for development through the MIRALOGX line of credit propels MIRA into an exciting phase of innovation and development."

Intelligent Bio Solutions Inc. Reports Fiscal 2024 First Quarter Financial Results and Operational Highlights

Retrieved on: 
Wednesday, November 8, 2023
Auctus, FDA, Ketamine, Mining, Government, Acquisition, Aviation, Growth, Agriculture, Tramadol, ISO, Intelligence, Cryptocurrency, Pharmaceutical industry

NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for its fiscal first quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • First Quarter & Recent Highlights:
    Expanded into the New Zealand market, representing a significant milestone in the Company’s growth strategy for its Intelligent Fingerprinting Drug Screening System.
  • Enhanced customer portfolio with specialist container logistics firm VKVP Haulage adopting the Company’s Intelligent Fingerprinting Drug Screening System.
  • Additionally, existing customer Auctus Management Group completed 25,000 tests using the Company’s Intelligent Fingerprinting Drug Screening System.
  • First Fiscal Quarter Ended September 30, 2023, Financial Results
    All amounts are expressed in U.S. dollars unless indicated otherwise.

AltaPointe's Behavioral Health Crisis Center Offers Innovative Approach to Fentanyl Addiction Treatment Using Ketamine in Combination with Buprenorphine

Retrieved on: 
Thursday, November 9, 2023
BHCC, Buprenorphine, Ketamine, Heroin, Patient, Fentanyl, Chronic pain, Pharmaceutical industry, Cereal, Buprenorphine/naloxone

MOBILE, Ala., Nov. 8, 2023 /PRNewswire-PRWeb/ -- In the ongoing battle against the fentanyl epidemic, a promising new approach has emerged and AltaPointe Health is at the forefront. AltaPointe's Behavioral Health Crisis Center (BHCC) has started offering the use of ketamine to help transition a patient from fentanyl to buprenorphine (often referred to by the common brand name Suboxone), a proven addiction-treatment medicine.

Key Points: 
  • In the ongoing battle against the fentanyl epidemic, a promising new approach has emerged and AltaPointe Health is at the forefront.
  • AltaPointe's Behavioral Health Crisis Center (BHCC) has started offering the use of ketamine to help transition a patient from fentanyl to buprenorphine (often referred to by the common brand name Suboxone), a proven addiction-treatment medicine.
  • MOBILE, Ala., Nov. 8, 2023 /PRNewswire-PRWeb/ -- In the ongoing battle against the fentanyl epidemic, a promising new approach has emerged and AltaPointe Health is at the forefront.
  • AltaPointe's Behavioral Health Crisis Center (BHCC) has started offering the use of ketamine to help transition a patient from fentanyl to buprenorphine (often referred to by the common brand name Suboxone), a proven addiction-treatment medicine.

Daytryp Health Announces Partnership with Enthea for Groundbreaking Nationwide Availability of Ketamine-Assisted Therapy as an Employee Benefit

Retrieved on: 
Wednesday, November 8, 2023
Ketamine, DSM-5, MD, News, Health, Dr. Bronner's Magic Soaps, KAT, Doctor, Clinician, PTSD, Partnership, Brain, Depression, Patient, Mental health, Pharmaceutical industry

PHOENIX, Nov. 8, 2023 /PRNewswire-PRWeb/ -- Daytryp Health, Arizona's premier Ketamine Assisted Treatment (KAT) organization, which focuses on using Ketamine Therapy for a variety of mental health ailments, has entered into a partnership with Enthea.

Key Points: 
  • Chris Cohn, CEO of Daytryp Health
    Enthea is the first and only licensed provider of health benefit plans that cover psychedelic-assisted therapies.
  • Enthea is delighted to announce that it now has national network capabilities and is able to serve not only Arizona employers, but U.S. employers nationwide.
  • Daytryp is proud to partner with Enthea to help future-thinking employers offer Ketamine Therapy which have long lasting, transformative outcomes," said Chris Cohn, CEO of Daytryp Health.
  • This can result in long-term relief – and not merely symptom suppression, as is too often the case with today's conventional therapy."

Ketamine can rapidly reduce symptoms of PTSD and depression, new study finds

Retrieved on: 
Wednesday, November 8, 2023
Post-traumatic stress disorder, Patient, Ketamine, Suicide, Grammatical mood, Research, Survivor, Time, Food, Nightmare, Child abuse, Sertraline, Annals of Pharmacotherapy, Injection, Psychotherapy, Veteran, Trauma, Meta-analysis, PTSD, Disorder, Disease, Assault, LSD, Pharmacy, Population, Paroxetine, Depression, Anxiety, Food and Drug Administration Amendments Act of 2007, Pharmaceutical industry, Vaccine, Meat

The drug ketamine can reduce the symptoms of post-traumatic stress disorder, or PTSD, and symptoms of depression in patients as early as a day after injection.

Key Points: 
  • The drug ketamine can reduce the symptoms of post-traumatic stress disorder, or PTSD, and symptoms of depression in patients as early as a day after injection.
  • Patients receiving ketamine saw their PTSD symptoms reduced by about 25% both at one day and one week after therapy.
  • Ketamine might be an effective bridge to immediately reduce patients’ symptoms until trauma-focused psychotherapy and other antidepressants can kick in.
  • What still isn’t known
    The big unknown with using ketamine for PTSD and depressive symptoms is how often the injections are needed.

NRx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 14, 2023

Retrieved on: 
Tuesday, November 7, 2023
Ketamine, Telephone, UTI, DSM-IV codes, Webcast, Chronic pain, Pharmaceutical industry

RADNOR, Pa., Nov. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a late-stage biopharmaceutical company, today announced that it will release its third quarter 2023 financial results after the market closes on Tuesday, November 14, 2023, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/press-releases .

Key Points: 
  • RADNOR, Pa., Nov. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a late-stage biopharmaceutical company, today announced that it will release its third quarter 2023 financial results after the market closes on Tuesday, November 14, 2023, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/press-releases .
  • The Company will host a conference call to discuss the financial results as well as provide a corporate update at 4:30 p.m.
  • A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/events .
  • Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1-855-327-6837 or internationally +1 1-631-891-4304.

Pharma Industry Consortium to Present Data from large Ketamine-challenge Study at CNS Summit

Retrieved on: 
Monday, November 6, 2023
Science, Ketamine, Research, Janssen Pharmaceuticals, Psychiatry, CSO, EBS, Cognisable offence, Volunteering, Acquisition, Neuroscience, CNS, Schizophrenia, DSM-IV codes, Biomarker, Magnitude, Electrophysiology, Depression, ERP, TRD, Pharmaceutical industry, Medical imaging

LOUISVILLE, Nov. 6, 2023 /PRNewswire/ -- The ERP Biomarker Qualification Consortium announced today that they will be presenting data from a recently completed, pharma industry sponsored study that measured the electrophysiologic effects of ketamine on healthy brain function, at the CNS Summit 2023 in Boston.

Key Points: 
  • LOUISVILLE, Nov. 6, 2023 /PRNewswire/ -- The ERP Biomarker Qualification Consortium announced today that they will be presenting data from a recently completed, pharma industry sponsored study that measured the electrophysiologic effects of ketamine on healthy brain function, at the CNS Summit 2023 in Boston.
  • The EBS-B study was performed at CenExel Research and utilized the COGNISION® System for EEG/ERP acquisition and analysis.
  • The study results will be presented on two posters during the poster session on Thursday, November 9 at 5:00-7:00pm.
  • Studies that investigate biomarker reliability and seemingly 'paradoxical effects' on study endpoints prove the importance of precompetitive participation from industry and academic organizations."

NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression

Retrieved on: 
Monday, November 6, 2023
Partner, FDA, Good manufacturing practice, Suicide, Ketamine, Dark Enlightenment, US, Research, WEST, CDC, Caregiver, Partnership, United States Department of Veterans Affairs, New Drug Application, Depression, Safety, Nephron, Defense, Patient, Edward Hines Jr. Veterans Administration Hospital, Mental health, Pharmaceutical industry

Recent CDC data suggest that more than 3 million Americans have active thoughts of suicide and more than 50,000 die from suicide each year.

Key Points: 
  • Recent CDC data suggest that more than 3 million Americans have active thoughts of suicide and more than 50,000 die from suicide each year.
  • "There are few efforts as important as playing a role - through research and development - in tackling the nation's mental health crisis," said Lou Kennedy CEO and owner of Nephron Pharmaceuticals.
  • "To this end, we are honored to partner with NRx Pharmaceuticals in a groundbreaking endeavor.
  • Together, we are advancing the production of single-dose, intravenous Ketamine, which could be a crucial breakthrough for the treatment of depression.

AANA and APNA Issue Joint Statement on Ketamine Infusion Therapy for Psychiatric Disorders

Retrieved on: 
Friday, November 3, 2023
Post-traumatic stress disorder, Knowledge, Ketamine, Policy, Roger Hawkins (drummer), CRNA, PMH, DSM-IV codes, Person, APNA, Bipolar disorder, American Psychiatric Nurses Association, Doctor of Philosophy, Multimedia, Environment, DNP, FAAN, AANA, Certified Registered Nurse Anesthetist, Crna, Nursing, Patient, Diagnosis, Anesthesia, Communication, Mental health, Pharmaceutical industry

Together, AANA and APNA have issued the following statement regarding ketamine infusion therapy for psychiatric disorders:

Key Points: 
  • Together, AANA and APNA have issued the following statement regarding ketamine infusion therapy for psychiatric disorders:
    "The AANA and APNA recognize the expertise of certified registered nurse anesthetists (CRNAs), psychiatric-mental health registered nurses (PMH RNs), and psychiatric-mental health advanced registered nurses (PMH APRNs) who are educated and qualified to administer ketamine infusion therapy for psychiatric disorders in accordance with professional scope and standards of practice, federal and state law, and facility policy."
  • When administering ketamine for treatment of psychiatric disorders, CRNAs collaborate with psychiatric-mental health professionals whose practice includes diagnosing psychiatric disorders within their professional and state scope of practice.
  • As part of the collaboration, CRNAs obtain a referral or past medical records, including a psychiatric history, medication list, and diagnosis, prior to providing ketamine infusion therapy for psychiatric disorders.
  • This expertise makes them an ideal partner in the delivery of ketamine infusion therapy for psychiatric disorders," said AANA President Dru Riddle, PhD, DNP, CRNA, FAAN.